April 2, 2019
C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage
C3J’s pending merger with AmpliPhi Biosciences, which will create a clinical-stage phage leader, is on track to close in May…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 2, 2019
Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering
PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule…
April 2, 2019
Bicycle Therapeutics to Present at ELRIG’s Research & Innovation 2019 Conference
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
April 2, 2019
Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
April 2, 2019
PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey
Company recognized for service provider leadership among global customers Also named a 2019 CRO Leadership Award Winner BOSTON–(BUSINESS WIRE)–PAREXEL International…
April 1, 2019
Titan with enough to fund planned operations through the third quarter of 2019, Probuphine well-positioned for global success
Titan’s President and CEO, Sunil Bhonsle said that the second half of 2018 as the company’s rapid advancement toward becoming a commercial-stage company following its assumption of responsibility for Probuphine sales in the U.S. starting mid-June.
April 1, 2019
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
Ends 2018 with triad of innovative cell therapy technologies: UniverCyte™ for immune tolerance, PureStem® for cell derivation and manufacturing, and…
April 1, 2019
Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Merck [NYSE:MRK], known as MSD outside the United States and Canada, today announced…
April 1, 2019
Tricida Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares…
April 1, 2019
Novartis buys IFM Tre for $1.575 Billion from IFM Therapeutics
Novartis has purchased a subsidiary of IFM Therapeutics LLC focused on developing ani-inflammatory medicines targeting the NLRP3 inflammasome, which will add one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system.